The first randomized clinical trial (RCT), SYMPLICITY HTN-2, [2] demonstrated significant reductions in both systolic and diastolic BP in patients with RH. However, the initial excitement turned into skepticism when a large RCT, SYMPLICITY HTN-3, [3] using a sham procedure as placebo, failed to achieve its primary efficacy. More recently, RCTs on RDN in RH have also shown discrepant results. [4] [5] [6] [7] [8] [9] [10] A recent meta-analysis based on 7 RCTs in patients with RH reported that RDN with the SYMPLICITY systems did not significantly reduce BP compared to antihypertensive drugs at 6 months after the intervention. [11] Their conclusions, however, were drawn with the pooled effects with much heterogeneity. The aim of our study was to seek possible sources of clinical heterogeneity, identify homogeneous subpopulations, and reconduct a systematic review for the safety and efficacy assessment of RDN by those subpopulations. In addition to the seven trials reviewed by Fadl Elmula et al., [11] the present study further includes two more recent RCTs and evaluates both 6-and 12-month efficacy endpoints. [4, 5] 
Methods

Data sources
Publications in English or Chinese were identified by searching PubMed, Medline, Embase, and the Cochrane Central Register of Controlled Trials available up to June 2016. Search terms included "hypertension" and "blood pressure" and "denervation" and "RDN". A more detailed search strategy is described in Supplementary text 1, and a flow diagram for study selection is shown in Figure 1 .
Study selection
We included all RCTs on human subjects that assessed the effect of RDN as the additional treatment to current antihypertensive drugs in use, and compared it with the continuation of antihypertensive drug use with or without a sham procedure. Use of the sham procedure in control group was not required for inclusion. We excluded single arm studies, meeting abstracts, letters, and case reports.
The inclusion criteria for eligible studies included (1) adult patients (>18 years old) with RH, defined as office BP >140/90 mmHg (1 mmHg = 0.133 kPa) or 24-h systolic BP (24-h SBP) >130 mmHg or 24-h daytime SBP >135 mmHg, in spite of the concurrent use of 3 antihypertensive agents of different classes at optimal dose amounts, including a diuretic; [1] (2) patients who underwent RDN using percutaneous catheters and radiofrequency probes; and (3) BP records measured as ambulatory BP or/and office BP at baseline and 6-month follow-up, or BP change from baseline to 6-month follow-up.
Outcomes
The primary outcomes were 24-h SBP and office SBP changes from baseline to 6-month and 12-month follow-ups, severe cardiovascular events rate, and all-cause mortality. The severe cardiovascular events included myocardial infarction, new-onset heart failure, stroke, hypertension crisis, angina needing a coronary stent, embolic event resulting in end-organ damage, and hospitalization for atrial fibrillation. The secondary outcomes were changes in 24-h diastolic BP (24-h DBP), office diastolic blood pressure (office DBP) at 6-month follow-up, and adverse events of RDN.
Data extraction, synthesis, and quality assessment
The following was extracted: the name of the first author, publication year, region, study design, total participants, number of participants receiving RDN, number of participants in the control group, trial inclusion and exclusion criteria, type of catheter used, method of BP measurement, maximal length of follow-up, office systolic and diastolic BP, 24-h SBP and DBP, daytime ambulatory SBP at baseline, 6-, 12-, 36-month follow-ups in both groups, and procedural complications. The methodological quality of RCTs was assessed independently by two reviewers using Jadad Scale.
[12] The Jadad Scale is an assessment score based on the degree of participant randomization, application of the blinding method, and report of study withdrawals and dropouts. A threshold of ≥4 points is regarded as a high-quality study. [12] The risk of bias was assessed independently by two reviewers using the Cochrane Collaboration's tool. This tool evaluates each study in the following six specific domains: adequate random sequence generation, allocation sequence concealment, blinding of subjects/outcome assessors, incomplete outcome data, free of selective outcome reporting, and free of other bias. Every domain was scored to be high risk of bias, low risk of bias, or unclear. The overall assessment of each RCT was graded as "low risk" (if all the domains were assessed as low risk of bias), "unclear" (if there exists at least one domain unclear), or "high risk" otherwise. [13] With no disagreement between the reviewers in the list of studies included in the meta-analysis and their quality assessment, a third reviewer was waived.
Statistical analysis
We used a random effects model to combine the studies given significant heterogeneity in the treatment effects. The heterogeneity was statistically evaluated by the I 2 statistic, where values of 0-24.9%, 25-49.9%, 50-74.9%, and 75-100% indicated no, mild, moderate, and severe heterogeneity, respectively. [14, 15] Extensive subgroup analyses were carried out to minimize possible sources of clinical heterogeneity by the (1) baseline SBP level, (2) frequency of antihypertensive medication changes, (3) race, and (4) coronary heart disease (CHD) prevalence. For survival outcomes, relative risk (RR) was used to assess the effect of treatment, while mean difference (MD) was used for continuous outcomes, along with the corresponding 95% confidence interval (CI ). Two-tailed P < 0.05 was considered statistically significant. All statistical analyses were carried out using Review Manager 5.3 software (Nordic Cochrane Center, Copenhagen, Denmark).
results
Study characteristics
We identified 9 RCTs that met the inclusion criteria with a total of 1068 patients [ Table 1 ]. All had similar inclusion criteria, except for one trial [6] [Supplementary Table 1] that enrolled mild RH patients who had 24-h SBP/DBP level just above 140/78 mmHg at baseline. In two trials, only ambulatory BP measurements [5, 6] were available, while both office and ambulatory BP were collected in the seven remaining trials. The maximum length of follow-up was at least 6 months in all studies, and up to 12 months in three trials [16] [17] [18] and 36 months in one trial. [19] There were five other trials [2, 3, 5, 6, 9] designed not to alter antihypertensive medication during the follow-up. In contrast, the baseline antihypertensive medication was allowed to be modified in four trials. [4, 7, 8, 10] Three trials [6, 7, 10] included only white population and one trial [9] included only Asian population. Regarding the patients given the antihypertensive drugs at baseline and 6-month follow-up, their characteristics are described in Supplementary Table 2 . Only one trial [7] had reported that more antihypertensive drugs were used after 6 months in the control group, on average, than the RDN group (+0.3 drugs). Regarding the baseline BP severity, there were three studies [2, 3, 9] with baseline office SBP ≥175 mmHg, over 10-25 mmHg higher than that of other trials. Baseline level of 24-h SBP was not available in SYMPLICITY HTN-2.
[2] The other two studies [3, 9] with baseline 24-h SBP ≥155 mmHg were about 7-24 mmHg higher than that of other trials. As shown in Table 2 , the Cochrane Collaboration's assessment suggested that most studies were at a high risk due to lack of blinding. However, the methodological quality of all included studies was rated as "high" [i.e., Jadad scale was ≥5 in Table 2 ].
Whole group analysis of 24-h systolic blood pressure and office systolic blood pressure at 6-month follow-up
We meta-analyzed BP outcomes from a total of nine RCTs. Summary of analysis results of the nine individual studies is provided in Table 3 . The pooled effect of RDN, as the difference from the baseline BP level between RDN and control groups, was MD = −1.1 mmHg [95% CI: −4.7-2.5 mmHg; P = 0.55; Figure 2 ] for 24-h SBP, and MD = −2.55 mmHg [95% CI: −12.90-7.80 mmHg; P = 0.63; Figure 3 ] for office SBP. Given much heterogeneity in 24-h SBP (I 2 = 67%) and office SBP (I 2 = 90%), this study further conducted subgroup analyses and sensitivity analyses.
Subgroup analysis of 24-h systolic blood pressure at 6-month follow-up By systolic blood pressure at baseline Subgroup analysis results by baseline 24-h SBP level (≥155 mmHg or <155 mmHg) are shown in Figure 4 . In the subpopulation with baseline 24-h SBP ≥155 mmHg, the pooled effect of RDN was marginally significant (MD = −2.92 mmHg; 95% CI: −6.36-0.53 mmHg; P = 0.10). There was no significant difference between two groups in the subpopulation with baseline 24-h SBP <155 mmHg (P = 0.61).
By frequency of medication changes
Among the nine trials, three trials [2, 6, 9] with the medication change rate below 25% were categorized as the "infrequent medication change" group. The remaining six trials [3] [4] [5] 7, 8, 10] categorized as the "frequent medication change" group. In the infrequent medication change subgroup, the use of RDN resulted in a significant reduction in 24-h SBP level at 6 months [MD = −4.88; 95% CI: −8.54-−1.22 mmHg; P = 0.009; Figure 5 ]. Whereas, in the frequent medication [7] 2016, [16] 2017 [20] (NCT01560312) [2] 2012, [17] 2014, [18] (NCT00888433) [3] 2015, [19] (NCT01418261) 
Asian (%) (R/C)
DENERHTN 2015 [8] (NCT01570777) Prague-15 2015, [7] 2016, [16] 2017 (NCT01560312) 56/59 100/100 0/0 0/0 6/7 22/17 84/80
ReSET 2015 [5] (NCT01762488) [2] 2012, [17] 2014, [18] (NCT00888433) [3] 2015, [19] (NCT01418261) change subgroup, the difference between RDN and control was not statistically significant [MD = 1.41; 95% CI: -3.61-6.44 mmHg; P = 0.58; Figure 5 ].
By race
In both Asian [9] and white [6, 7, 10] subpopulations, the effect of RDN was not significantly different in lowering 24-h SBP [I 2 = 66% in white subgroup, Supplementary Figure 1 ].
Improvement in heterogeneity
For 24-h SBP and with all 9 trials included, I 2 = 67%. By restricting to trials with an average baseline SBP ≥155 mmHg, [3, 9] the heterogeneity reduced to I 2 = 17%. The restriction to the trials with medication change rate <25% [2, 6, 9] resulted in no heterogeneity (I 2 = 0%). By restricting the trials with white subpopulation, [6, 7, 10] the heterogeneity remained similar at 66%. By prevalence of coronary heart disease Six trials [2] [3] [4] 7, 8, 10] reported the percentage of patients with CHD [ Table 1 ]. From these reports, we have noticed that the prevalence of CHD varied considerably not only between the reviewed trials but also within the trial. As an example of the between-trial comparison, 60% of RDH patients (and 47% of control) had CHD in the SYMPLICITY-FLEX trial, whereas 6% of RDN patients (and 7% of control) had CHD in the Prague-15 trial. The OSLO trial was a good example of the within-trial comparison, where the trial was conducted under the most unbalanced study design with respect to the CHD prevalence (i.e., 11% of RDN and 60% of control patients had CHD). Therefore, we viewed the prevalent CHD as a potential source of clinical heterogeneity in trials and have identified three homogeneous subpopulation by (1) balanced CHD prevalence between RDN and control, [3, 7] (2) a higher prevalent CHD in RDN, [2, 8] and (3) a higher prevalent CHD in control. [4, 10] In the subgroup of the higher prevalent CHD in control, the control treatment was significantly better than RDN in office SBP reduction at 6 months [MD = 16.59; 95%
CI: 6.94-26.25 mmHg; P < 0.001; Supplementary Figure 4] . In contrast, in the other subgroups by the higher CHD prevalence in RDN and the balanced CHD prevalence subgroups, there was no significant difference between the two therapies [ Supplementary Figure 4 ].
For office SBP, when all seven trials [2] [3] [4] [7] [8] [9] [10] were included, there was severe heterogeneity (I 2 = 90%). Even if we restrict the pooled analysis to trials with an average baseline SBP ≥175 mmHg [2, 3, 9] or trials with medication change rate <25%, [2, 9] the heterogeneity level still remained high (I 2 = 94% and I 2 = 88%). However, when the prevalence of CHD was considered, the heterogeneity reduced to 0% in the subgroup defined as a higher CHD prevalence in controls, and I 2 = 9% in the subgroup defined as a balanced CHD prevalence.
Whole group analysis of office systolic blood pressure at 12-month follow-up
The office SBP, at 12-month follow-up, was available for the pooled analysis of two trials. [16, 19] There was no significant difference between the two groups [MD = 0.69 mmHg; 95% CI: −4.2-5.58; P = 0.78; Figure 6 ], and no heterogeneity of the pooled effect (I 2 = 0%; P = 0.37).
Whole group analysis of 24-h diastolic blood pressure and office diastolic blood pressure at 6-month follow-up
Regarding DBP outcomes, this analysis showed that the BP decrease was not statistically significant [MD = 0.14; 95% CI: −1.72-2.00 mmHg; P = 0.88; Supplementary Figure 
Sensitivity analysis
By excluding one trial at a time, we assessed sensitivity of meta-analysis. Although the approach reduced the level of heterogeneity to some extent in some cases, in most cases, it could not resolve the issue. Summary of sensitivity analysis is provided in Supplementary Tables 3-6. 
Severe cardiovascular events and mortality
In five RCTs, [2, 3, 5, 7, 10] severe cardiovascular events were reported. The conclusions from these trials were consistent with our meta-analysis in that there was no statistical difference in the risk of severe cardiovascular events rate between two groups [RR = 1.43; 95% CI: 0.84-2.45; P = 0.19; I 2 = 0; Supplementary Figure 7] . Only one trial studied mortality as outcome measure, [3] where there was no significant difference in the risk of mortality rate between two groups (RR = 0.97; 95% CI: 0.09-10.61; P = 0.98).
Other adverse effect
In general, adverse events rarely occurred, while a pseudoaneurysm was the most frequent adverse event among them [Supplementary Table 7] .
dIscussIon Elevated sympathetic nervous system activity is crucial for the development and progression of systemic hypertension, by regulating renin release, tubular sodium reabsorption, and renal blood flow. [21] Afferent sympathetic nerves from the kidney contribute to regulation of whole-body sympathetic activity. [22] An early clinical evaluation has demonstrated that catheter-based RDN could lower BP in patients with RH by decreasing renal norepinephrine spillover, halving of renin activity, increasing renal plasma flow, and reducing central sympathetic drive. [23] However, RCTs designed to confirm the early clinical evaluation results have shown controversial results. Moreover, the results of Fadl Elmula et al.'s meta-analysis based on 7 trials revealed highly significant heterogeneity.
[11] The present study, based on 9 RCTs, attempted to deal with the heterogeneity and find main reasons for the discrepant results among RCTs by conducting extensive subgroup and sensitivity analyses.
We considered both 24-h SBP and office SBP as the primary outcomes. Pooling all nine RCTs available, there was no difference between RDN and control in lowering SBP. However, an interesting finding is that, in the subpopulation with baseline 24-h SBP ≥155 mmHg, the effect of RDN was significantly better than control. Given that the patients with a higher BP tend to have an over-active sympathetic nerve system, [24] this finding might be explained by that the catheter-based RDN works better in decrease the sympathetic nerve activity than usual antihypertensive drugs. The role of the catheter-based RDN has been proven that it blocks the pathway of sympathetic nerve activation through a reduction whole-body norepinephrine spillover, which results in a sustained BP reduction. [23] In contrast, antihypertensive drugs that directly block the sympathetic activity directly were rarely used due to obvious adverse effects. This mechanism may also explain the nonsignificant RDN effect in mild RH (daytime SBP between 135 and 149 mmHg or daytime ambulatory DBP between 90 and 94 mmHg). [6] Another interesting finding is that, with patients changing their antihypertensive medications less frequently, this meta-analysis showed a significantly better effect on lowering 24-h SBP by the 6-month follow-up. We suspected that the reason for inconsistent conclusions by the individual nine studies (and the extremely high heterogeneity in the pooled analysis) might be because antihypertensive drugs were too frequently changes in most studies. Conducting the subgroup analysis with low medication change rates resolved this issue.
As demographic discrepancy in the study populations might contribute to inconsistent findings, we conducted subgroup analysis by race. Our results were consistent: no significant BP reduction at 6-month follow-up has been found in both Asian and white subpopulations.
There are a few limitations in this study. First, in subgroup analyses, the sample size was relatively small. However, significant differences were detected, which had not been observed in the pooled analyses with much larger sample sizes due to the severe heterogeneity. Second, due to lack of the longer follow-up details available, effects within 6 and 12 months after the intervention have been assessed. It is worth assessing a long-term effect (longer than 1-year follow-up), given that, in SYMPLICITY HTN-3, the 12-month office SBP change was greater than that observed at 6 months in RDN group. Further studies based on randomized controlled trials are needed to assess a successful ablation of RDN, while completely solving these issues and accounting for various BP levels and the sympathetic neural activity at the same time. This analysis focused on the catheter-based RDN. There are a few more RCTs still ongoing, which aim to evaluate the effect of RDN on decreasing BP [Supplementary Table 8 ]. The results of the clinical studies will affect the future of RDN.
Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website.
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Supplementary Figure 4:
Forest plot for mean difference in office SBP at 6-month follow-up by CHD subgroup. Balanced CHD prevalence: balanced coronary heart disease prevalence between both groups; High CHD prevalence in Control: CHD prevalence in control group was higher than that in RDN group; High CHD prevalence in RDN: CHD prevalence in RDN group was higher than that in control group; CI: Confidence interval; CHD: Coronary heart disease; RDN: Renal denervation; SBP: Systolic blood pressure. 
Supplementary
Supplementary Figure 7:
Forest plot for severe cardiovascular events at 6-month follow-up. Severe cardiovascular events: Myocardial infarction, new-onset heart failure, stroke, hypertension crisis, angina needing a coronary stent, embolic event resulting in end-organ damage, and hospitalization for atrial fibrillation; CI: Confidence interval; RDN: Renal denervation. ; patients currently on treatment with an aldosterone receptor blocker or who had previously received one of such class of drugs and had been withdrawn because of lack of efficacy and/or adverse effects; patients unlikely compliant with treatment. Other exclusion criteria comprised prerandomization serum potassium level at least 5.5 mmol/L, pregnant women, significant valvular heart disease, or the occurrence of a major vascular event (myocardial infarction, unstable angina, or stroke) within 6 months before the study enrolment OSLO RH was defined as uncontrolled hypertension (office SBP >140 mmHg), despite regular intake of maximally tolerated doses of ≥3 antihypertensive drugs including a diuretic. In addition, patients had to qualify by having mean ambulatory daytime SBP >135 mmHg immediately patients could be 18-80 years of age with normal renal arteries at CT or MRI examination within 2 years before participation
Supplementary
Patients with secondary and spurious hypertension, and some patients with high serum aldosterone levels (primary hyperaldosteronisme without tumor or with high aldosterone/renin activity ratio) who responded to treatment with spironolactone, were identified and excluded. Patients with estimated glomerular filtration rate <45 ml·min −1 ·1.73 m −2 (MDRD formula), urine albumin/creatinine ratio >50 mg/mmol or type 1 diabetes mellitus could not be included in line with the hitherto single published randomized study of BP-lowering effects of RDN Prague- 15 RH with office systolic BP of >140 mmHg; SBP of >130 mmHg during 24-h ambulatory BP monitoring; treatment with at least three antihypertensive medications, including diuretics, at optimal doses; age of >18 years; signed informed consent Any secondary form of hypertension; noncompliance with medical treatment; presence of any chronic renal disease (serum creatinine level of >200 mmol/L); pregnancy; history of myocardial infarction or stroke in the previous 6 months; The presence of severe valvular stenotic disease; anatomical abnormality or a variant structure of either renal artery, including aneurysm, stenosis, a reference diameter of <4 mm, and a length of <20 mm; an increased bleeding risk (thrombocytopenia of <50,000 platelets/ml of blood and an INR of >1.5) ReSET Aged 30-70 years; one month of stable antihypertensive treatment with at least three antihypertensive agents including a diuretic (or in case of diuretics intolerance a minimum of three nondiuretic antihypertensive drugs); daytime ABPM SBP ≥145 mmHg (preceded by 14 days of scheduled drug intake showing at least 85% adherence)
General: Noncompliant personality (abuse and mental illness); pregnancy/inadequate contraception in fertile women; known allergy to iodine-containing radiograph contrast agent; comorbidity: Secondary hypertension; malignant disease; congestive heart failure NYHA 3-4; chronic renal failure stage 4-5 (eGFR ≤30 ml·min ); stable angina pectoris CCS class 2-4; unstable angina pectoris; coronary artery disease with indication for coronary intervention; recent myocardial infarction or coronary intervention (<6 months); permanent atrial fibrillation; orthostatic syncope (<6 months); symptomatic peripheral artery disease; paraclinical: clinically significant abnormal electrolytes and liver function tests; hemoglobin <7.0 mmol/L; abnormal thyroidea function; macroscopic hematuria; ECG: Atrioventricular block Grades 2 and 3; Echocardiography: Left ventricular ejection fraction <50%; significant valvular disease; computed axial tomography Contd... , type 1 diabetes, contraindications to MRI, substantial stenotic valvular heart disease, pregnancy or planned pregnancy during the study, and a history of myocardial infarction, unstable angina, or cerebrovascular accident in the previous 6 months SYMPLICITYHTN -3 Patients with severe RH were prospectively enrolled in the study. On initial screening, patients were required to have a SBP of 160 mmHg or higher (average of three measurements at an office visit [hereafter referred to as office BP] while the patient was seated) and to be taking maximally tolerated doses of three or more antihypertensive medications of complementary classes, one of which had to be a diuretic at an appropriate dose. No changes in antihypertensive medication in the previous 2 weeks were allowed. For the next 2 weeks, patients recorded their BP at home (hereafter referred to as home BP) in the morning and in the evening and kept a diary indicating their adherence to medical therapy. Then, a confirmatory screening visit occurred, during which the SBP of 160 mmHg or higher was confirmed, adherence to medications was documented, and automated 24-h ambulatory blood pressure monitoring was performed to ensure a SBP of 135 mmHg or higher Secondary causes of hypertension and >1 hospitalization for a hypertensive emergency in the previous year. Renal-artery stenosis of >50%, renal-artery aneurysm, prior renal-artery intervention, multiple renal arteries, a renal artery of <4 mm in diameter, or a treatable segment of <20 mm in length 
